Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Bio-Rad Laboratories (BIO) one of those stocks right now? A quick glance at the ...
Bio-Rad is back on the table as an attractive value proposition once again. The firm is well-positioned to unlock tremendous value for shareholders looking ahead, in my estimation. Profitability is a ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Most of Kelderman's pay was in ...
Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the ...
Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for ...
Bio-Rad Laboratories, Inc. BIO posted fourth-quarter 2024 adjusted earnings per share (EPS) of $2.90, which missed the Zacks Consensus Estimate of $2.93 by 1.0%. The bottom line decreased 6.4% from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results